Alpha Cubed Investments LLC Has $2.49 Million Holdings in Gilead Sciences, Inc. (GILD)

Alpha Cubed Investments LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 30,718 shares of the biopharmaceutical company’s stock after selling 2,024 shares during the period. Alpha Cubed Investments LLC’s holdings in Gilead Sciences were worth $2,489,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of GILD. Keel Point LLC boosted its position in shares of Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 12 shares during the period. Paradigm Financial Advisors LLC boosted its position in shares of Gilead Sciences by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares during the period. West Oak Capital LLC boosted its position in shares of Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the period. First Heartland Consultants Inc. boosted its position in shares of Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the period. Finally, Princeton Portfolio Strategies Group LLC boosted its position in shares of Gilead Sciences by 0.4% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 41 shares during the period. Institutional investors own 75.94% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) traded down $0.04 on Friday, hitting $79.02. The stock had a trading volume of 6,370,000 shares, compared to its average volume of 8,150,000. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The firm has a market capitalization of $103,190.00, a PE ratio of 8.99, a P/E/G ratio of -1.58 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the previous year, the firm earned $2.75 earnings per share. The business’s revenue was down 13.2% compared to the same quarter last year. equities research analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.66%.

In related news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the transaction, the executive vice president now owns 64,613 shares of the company’s stock, valued at $4,772,962.31. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 in the last quarter. Insiders own 1.30% of the company’s stock.

Several analysts have recently issued reports on the company. BidaskClub cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday. Leerink Swann increased their price objective on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research note on Thursday, October 19th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Mizuho increased their price objective on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Finally, Bank of America reduced their price objective on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $85.03.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://ledgergazette.com/2018/01/13/gilead-sciences-inc-gild-shares-sold-by-alpha-cubed-investments-llc.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply